Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tandem Diabetes CareLTS:0M0F -2.09%68 Piotroski F-Score is 6 as of Jul. 13, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $29.79 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Tandem Diabetes Care ranks better than 81.07% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Tandem Diabetes Care has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Tandem Diabetes Care's Piotroski F-Score or its related term are showing as below:
LTS:0M0F'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 7
Current: 6
During the past 13 years, the highest Piotroski F-Score of Tandem Diabetes Care was 7. The lowest was 1. And the median was 4.
Tandem Diabetes Care (LTS:0M0F) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Tandem Diabetes Care Piotroski F-Score Related Terms
Tandem Diabetes Care Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M0F vs CNMD, AORT, LMRI: Piotroski F-Score Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Tandem Diabetes Care's current Net Income (TTM) was -95.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Tandem Diabetes Care's return on assets of this year was -0.10252965. Tandem Diabetes Care's return on assets of last year was -0.19538492.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Tandem Diabetes Care's gearing of this year was 0.75910371. Tandem Diabetes Care's gearing of last year was 0.45677717.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Tandem Diabetes Care's current ratio of this year was 3.57760759. Tandem Diabetes Care's current ratio of last year was 2.30219485.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Tandem Diabetes Care's number of shares in issue this year was 68.397. Tandem Diabetes Care's number of shares in issue last year was 66.404.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Tandem Diabetes Care's gross margin of this year was 0.54927083. Tandem Diabetes Care's gross margin of last year was 0.5222122.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Tandem Diabetes Care's asset turnover of this year was 1.1142903. Tandem Diabetes Care's asset turnover of last year was 1.04453135.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
0
+
1
+
0
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Tandem Diabetes Care has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Tandem Diabetes Care (LTS:0M0F) has a Piotroski F-Score of 6 as of Jul. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tandem Diabetes Care and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Tandem Diabetes Care's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Tandem Diabetes Care ranks #152 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Tandem Diabetes Care's Piotroski F-Score too high?
Tandem Diabetes Care's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Tandem Diabetes Care's value of 6 is 20% above this industry median. Based on the distribution chart, Tandem Diabetes Care ranks #152 out of 803 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Piotroski F-Score compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #152 out of 803 companies for Piotroski F-Score. This places Tandem Diabetes Care in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Tandem Diabetes Care's value of 6 is 20% above this benchmark. Historically, Tandem Diabetes Care's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Tandem Diabetes Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tandem Diabetes Care's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.79, compared to a current price of $15.19 — trading 49% below its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Piotroski F-Score is 6 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $15.19 is trading 49% below its estimated GF Value™ of $29.79.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
GF Value™: $29.79 vs. price of $15.19 (49% below fair value)
Industry Position: 20% above the Medical Devices & Instruments median (#152 of 803)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score
Get the complete analysis for LTS:0M0F
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
